Ravi Parikh, MD, MPP, discusses the future of oncology practice, including real-world data, patient engagement, emerging technologies, and policy priorities shaping cancer care.
Feature|Articles|February 18, 2026
Precision Oncology and the New Era of Lung Cancer
Author(s)Sabrina Serani, Bruna Pellini, MD
Fact checked by: Andrea Eleazar, MHS
Discover how precision lung cancer care tackles gene fusions, new HER2/ROS1/ALK drugs, expanded screening, and liquid biopsies shaping 2026 treatment.
Advertisement
Advertisement
The landscape of thoracic oncology has undergone a seismic shift over the last 2 decades. Where once a diagnosis of advanced lung cancer offered few paths forward, the advent of precision medicine has transformed the field into one of the most dynamic areas of modern medicine. Bruna Pellini, MD, chief of Thoracic Medical Oncology at Baptist Health Miami Cancer Institute, specializes in treating uncommon mutations and discussed how to navigate the increasingly complex web of targeted therapies.
Related to this article
Telisotuzumab adizutecan showed promising survival in pretreated nonsquamous NSCLC, with the most benefit in EGFR wild-type tumors with high c-Met levels.
Renuka Iyer, MD, discusses clear documentation for AI ambient scribes and why multidisciplinary tumor boards remain essential in neuroendocrine tumor care.
Aman Chauhan, MD, reviews DAREON-7 data on obrixtamig plus chemotherapy in DLL3-positive neuroendocrine carcinoma, including response rates by DLL3 level.
Jacob Sands, MD, of Dana-Farber Cancer Institute, discusses survival gains, durability, and safety of tarlatamab plus durvalumab in the phase 3 DeLLphi-305 trial.
FDA issues a not approvable letter for Novocure’s Optune Mya in NSCLC brain metastases, citing uncertain clinical benefit. No safety concerns were raised.
Updated phase 2 data showed a 60% ORR and 86% CNS ORR with frontline silevertinib in non-classical EGFR-mutant NSCLC; FDA discussion supported a phase 3 trial in 2027.
Imneskibart showed promising outcomes and tolerability in patients who had previously received immune checkpoint inhibition for either melanoma or lung adenocarcinoma.
Advertisement
Advertisement